Viehbacher, "Biogen") announced today that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI®" has been launched in South Korea. LEQEMBI received the Ministry of ...

Investors in innovation, like Cathie Wood, the CEO of ARK Investment Management ... the decline in MS revenue and the rise in ...

A third trial failure this year for the same experimental neurological drug has led Sage Therapeutics to discontinue ...

The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue ...

Investors in innovation, like Cathie Wood, the CEO of ARK Investment ... and the rise in new drugs for rare diseases, depression, and Alzheimer’s, analysts view Biogen Inc. (NASDAQ:BIIB) as ...

Sage said in its recent third-quarter earnings that it and Biogen would not pursue further development of zuranolone as a treatment for major depressive disorder, citing the “significant new ...

Ronald McDonald House Charities of South Louisiana(RMHCSLA) is pleased to welcome Ryan Furby and Duncan Brown to its Board of ...

especially for the individuals and families affected by Huntington’s disease who have long awaited new treatment options,” ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Investors in innovation, like Cathie Wood, the CEO of ARK Investment Management ... Spinraza was introduced to the market by ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...

Meanwhile, some companies such as Biogen, U.S. Bancorp and Western Midstream Partners added new positions to steer ... said it has appointed Luis Rojo as CEO and president, effective immediately.